Shots:
- The CHMP has adopted a positive opinion recommending the marketing authorization of Abevmy (inj. bevacizumab 100 & 400mg), which is co-developed by Biocon and Viatris
- The companies expect the EC’s decision in May’2021, which will grant the approval in 27 EU member countries and EEA member states of Norway, Iceland and Liechtenstein. For the UK, MHRA’s reliance procedure” will be followed, and the UK marketing authorization can be expected shortly after the EC decision
- Abevmy is a biosimilar referencing Roche’s Avastin and is a humanized mAb that selectively binds to human VEGF and neutralizes its biological activity. Abevmy is available for all indications of its reference products
Click here to read full press release/ article | Ref: Biocon Biologics | Image: PRNewswire
The post Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab) first appeared on PharmaShots.
